A prospective pharmacogenetic study of 5FU/LV in high-risk stage II and III colon cancer patients.

被引：0
|
作者：
Mulder, K [1 ]
Scarfe, AG [1 ]
Koski, S [1 ]
Au, HJ [1 ]
Butts, C [1 ]
Fields, A [1 ]
Razavy, H [1 ]
Graham, K [1 ]
Cass, CE [1 ]
Sawyer, MB [1 ]
机构：
[1] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2067
引用
收藏
页码：143S / 143S
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Adjuvant FOLFOX and 5FU/LV Chemotherapy for Patients with Stage II Colon Cancer
    Ayvaci, Mehmet U. S.
    Shi, Jinghua
    Alagoz, Oguzhan
    Lubner, Sam J.
    MEDICAL DECISION MAKING, 2013, 33 (04) : 521 - 532
  • [2] Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU plus Ox).
    O'Connell, Michael
    Lee, Mark
    Lopatin, Margarita
    Yothers, Greg
    Clark-Langone, Kim
    Millward, Carl
    Paik, Soonmyung
    Sharif, Saima
    Shak, Steven
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] THE 12-GENE COLON CANCER RECURRENCE SCORE (RS) PREDICTS RECURRENCE IN STAGE II AND III COLON CANCER PATIENTS TREATED WITH 5FU/LV (FU) AND 5FU/LV plus OXALIPLATIN (FU+OX): VALIDATION IN NSABP C07
    O'Connell, M. J.
    Lee, M.
    Lopatin, M.
    Yothers, G.
    Clark-Langone, K. M.
    Millward, C.
    Paik, S.
    Sharif, S.
    Shak, S.
    Wolmark, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 179 - 180
  • [4] Oxaliplatin/5FU/LV in stage II and III Colon Cancer: Updated results (as of January 04) for efficacy and neurotoxicity of the MOSAIC trial
    de Gramont, Aimery
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Hickish, Tamas
    Topham, Clare
    Bonetti, Andrea
    Clingan, Philip
    Marceau-Suissa, Jeanne
    Andre, Thierry
    ANNALS OF ONCOLOGY, 2004, 15 : 73 - 73
  • [5] Stage II patients in the "MOSAIC" trial evaluating Oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis
    Hickish, Tamas
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Bonetti, Andrea
    Clingan, Philip
    Figer, Arie
    Andre, Thierry
    de Gramont, Aimery
    ANNALS OF ONCOLOGY, 2004, 15 : 76 - 76
  • [6] Economic evaluation of adjuvant chemotherapy in Stage III (SIII) colon cancer: Capecitabine versus 5FU/LV.
    Virik, K.
    Skedgel, C.
    Younis, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 312S - 312S
  • [7] A prospective randomized phase III trial of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with stage II colon cancer
    Schippinger, W.
    Samonigg, H.
    Greil, R.
    Tschmelitsch, J.
    Steger, G.
    Jakesz, R.
    Gnant, M.
    Hofbauer, F.
    Rabl, H.
    Thaler, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer:: Efficacy results with a median follow-up of 4 years.
    de Gramont, A
    Boni, C
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Bonetti, A
    Clingan, P
    Marceau-Suissa, J
    Lorenzato, C
    André, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 246S - 246S
  • [9] Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?
    Bonin, Serena
    EBIOMEDICINE, 2015, 2 (08): : 780 - +
  • [10] Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
    Flejou, Jean-Francois
    Andre, Thierry
    Chibaudel, Benoist
    Scriva, Aurelie
    Hickish, Tamas
    Tabernero, Josep
    Van Laethem, Jean-Luc
    Banzi, Maria
    Maartense, Eduard
    Shani, Adi
    Carlsson, Goeran
    Scheithauer, Werner
    Papamichael, Demetris
    Moehler, Markus
    Landolfi, Stefania
    Demetter, Pieter
    Duval, Alex
    Lee, Mark
    Colote, Soudhir
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345